Ultime notizie per Nanobiotix (NASDAQ:NBTX) Azioni

Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix SA

JP Morgan analyst Michael Rehaut maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $48 to $58.

News

Price Target

Analyst Ratings

AZEK

JP Morgan Maintains Overweight on AZEK Co, Raises Price Target to $58

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $273 price target.

Reiteration

AAPL

Morgan Stanley Reiterates Overweight on Apple, Maintains $273 Price Target

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Overweight and raises the price target from $30 to $43.

TGTX

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43

Morgan Stanley analyst Devin McDermott maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $45 to $56.

Morgan Stanley Maintains Overweight on EQT, Raises Price Target to $56

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) has completed the second and final closing of its previously announced non-brokered private placement of its common shares at $0.06 per common share.
<h3 class="wp-block-heading">What Happened</h3>
The company said on Monday that, at the second closing of the offering, it issued 19,647,776 common shares for gross proceeds of roughly $1,178,867.
The second closing was in addition to the previously announced first closing in November when Decibel issued 33,503,864 common shares for gross proceeds of approximately $2,010,232.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel's $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Decibel said the proceeds of the offering will be used to work on and help integrate the integration of AgMedica BioScience Inc. which he company previously<a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance"> acquired</a>. The acquisition was arranged through an agreement with Callisto Capital on Oct. 28 and was made in exchange for a $6.3 million unsecured convertible debenture.
Decibel projects that AgMedica could contribute $30 million of net revenue and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro forma basis.
The company recently <a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">announced</a> its unaudited interim financial results on Thursday for the third quarter revealing CA$24.1 million ($17.2 million) in net revenue representing a 9% increase sequentially, but a 12% decrease year-over-year. However, gross margin before fair value adjustments reached 53% for the period, up from 44% in the prior year&#8217;s period, reflecting improved operational efficiency.
<h3 class="wp-block-heading">What's Next</h3>
The offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange (TSXV).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 1.45% higher at $0.0476 per share after the market close on Friday afternoon.

Cannabis

Financing

DBCCF

TSXV:DB

Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration

Morgan Stanley analyst Angel Castillo maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Overweight and raises the price target from $401 to $450.

Morgan Stanley Maintains Overweight on Deere, Raises Price Target to $450

EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) shares are trading higher after the company announced it entered into a definitive deal with funds managed by Blackstone Credit &amp; Insurance (BXCI) to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42159491/eqt-announces-3-5-billion-midstream-joint-venture-with-blackstone-credit-insurance" rel="noreferrer noopener">form a new midstream joint venture</a>.
As per the deal, BXCI will provide EQT&nbsp;$3.5 billion of cash consideration in exchange for a non-controlling equity interest in the joint venture.
This values the JV at approximately $8.8 billion, or 12x EBITDA. The deal provides EQT with a substantial equity capital solution at an accretive cost of capital.
EQT will also retain rights to growth projects linked to the contributed assets, including the planned Mountain Valley Pipeline expansion and the MVP Southgate project.
EQT intends to use the proceeds from the transaction to reduce its term loan, revolving credit facility, and redeem or tender senior notes.
Pro-forma for this deal, along with the recent sale of its remaining non-operated assets in northeast Pennsylvania, EQT expects to exit 2024 with approximately $9 billion in net debt.
EQT President and CEO&nbsp;Toby Z. Rice&nbsp;stated, &#8220;This transaction underscores the ultra-high-quality nature of EQT&#8217;s regulated midstream assets, which service one of the strongest power demand growth regions in&nbsp;the United States&nbsp;underpinned by long-term contracts with the region&#8217;s leading utilities.&#8221;
&#8221;Importantly, through this joint venture&nbsp;EQT preserves the benefits of the Equitrans acquisition by retaining the long-term value from synergy capture and growth projects. We look forward to working with Blackstone to optimize the value of these assets and together explore strategic opportunities across its leading portfolio of energy, power and digital infrastructure in the years ahead.&#8221;&nbsp;
EQT Chief Financial Officer&nbsp;Jeremy Knop&nbsp;stated, &#8220;Blackstone is a leader in providing capital solutions to large corporations and we are thrilled to partner with them in this unique transaction, crafting a tailor-made equity financing solution at a price significantly below EQT&#8217;s equity cost of capital while preserving key tax attributes. When we announced the Equitrans acquisition earlier this year, we made an unwavering commitment to debt reduction.&#8221;
&#8221;We have now delivered on that promise, with announced divestitures to date totaling&nbsp;$5.25 billion&nbsp;of projected cash proceeds, above the high-end of our&nbsp;$3 billion-$5 billion&nbsp;asset sale target, and several quarters ahead of schedule.&#8221;
The transaction is subject to customary closing adjustments, required regulatory approvals, and clearances, and is expected to close in the fourth quarter of 2024.
Investors can gain exposure to the stock via Invesco S&amp;P 500 Equal Weight Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPG#NYSE">RSPG</a>) and First Trust Natural Gas ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCG#NYSE">FCG</a>).
Price Action: EQT shares are up 3.22% at $47.40 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a></li>
</ul>

Equities

Large Cap

Movers

First Trust ISE-Revere Natural Gas Index Fund

RSPG

EQT Secures $3.5 Billion Boost: Blackstone JV To Power Midstream Expansion

Morgan Stanley analyst Lauren Schenk maintains Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) with a Overweight and raises the price target from $33 to $36.

CHWY

Morgan Stanley Maintains Overweight on Chewy, Raises Price Target to $36

JP Morgan analyst Seth Seifman maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Overweight and lowers the price target from $195 to $190.

JP Morgan Maintains Overweight on Boeing, Lowers Price Target to $190

Benchmark analyst Bill Sutherland downgrades Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Select Medical Hldgs to Hold

AMC's total domestic revenue for the weekend includes revenue from admissions, along with food &amp; beverage, including merchandise
4.6 million moviegoers watched a movie at AMC Theatres in the United States and at ODEON Cinemas, AMC's international subsidiary, from Thursday to Sunday
ODEON Cinemas recorded its single-day revenue high (admissions plus food &amp; beverage) in 2024 on Saturday, November 23
AMC's domestic merchandise program continues to be popular with guests as WICKED merchandise virtually sold out by Sunday
AMC will participate in the announced WICKED Singalong showtimes, coming to theatres later in December

AMC Theatres Achieves Record Domestic Revenue Pre-Thanksgiving Weekend With 4.6M Moviegoers, Driven by WICKED and GLADIATOR II, ODEON's Single-Day High, Nearly Sold-Out WICKED Merchandise, and Anticipates Upcoming WICKED Singalong Showtimes; No Financial Terms Disclosed

Morgan Stanley analyst Michael Cyprys upgrades Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Equal-Weight to Overweight and raises the price target from $24 to $55.

Upgrades

HOOD

Morgan Stanley Upgrades Robinhood Markets to Overweight, Raises Price Target to $55

MSTRRKLBNVDAACHRSAVATSLA$BTCLUNRMARAHOODData from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment " title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment ">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment </a>
<ul>
<li>MSTR</li>
<li>RKLB</li>
<li>NVDA</li>
<li>ACHR</li>
<li>SAVA</li>
<li>TSLA</li>
<li>$BTC</li>
<li>LUNR</li>
<li>MARA</li>
<li>HOOD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

ACHR

LUNR

MARA

MSTR

NVDA

RKLB

SAVA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 25, 2024 (Via Swaggy Stocks)

Bernstein analyst Gautam Chhugani maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and raises the price target from $290 to $600.

Bernstein Maintains Outperform on MicroStrategy, Raises Price Target to $600

Onto Innovation's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) short percent of float has fallen 14.24% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 2.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Onto Innovation Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732544122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Onto Innovation has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Onto Innovation's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Onto Innovation's peer group average for short interest as a percentage of float is 7.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ONTO

(ONTO) - Analyzing Onto Innovation's Short Interest

Genpact's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) short percent of float has risen 12.09% since its last report. The company recently reported that it has 5.20 million shares sold short, which is 3.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Genpact Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732544117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Genpact has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Genpact's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Genpact's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Genpact?

Perhaps obviously, the real estate industry is facing an uphill challenge heading into 2025, with global elections, financing costs and mounting debt maturities being the most pressing concerns, according to the Counselors of Real Estate&#8217;s (CRE) annual Top Ten Issues report.
Don't Miss:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
The report points to an industry grappling with unprecedented uncertainty. At the front is an estimated $2.5 trillion in commercial loan debt set to mature by 2026, forcing a reckoning in property valuations and financing structures.
&#8220;Whether the Fed reduces rates four times or two or three or five, rates are not going down to zero,&#8221; Anthony DellaPelle, CRE&#8217;s 2024 global chair, said at a conference last week. &#8220;I don&#8217;t think you&#8217;ll see people get mortgages under 3% for a long, long time unless something weird happens and I don&#8217;t wish that upon us.&#8221;
The rising cost of property insurance adds another layer of uncertainty to the market. Insurance companies, <a href="https://www.benzinga.com/real-estate/24/07/39618448/home-insurance-crisis-spares-these-states-with-minimal-rate-increases-how-much-did-climate-change-af">facing increased risk from extreme weather events and property damage</a>, have continued to raise premiums. The trend directly impacts property values and transaction feasibility across all sectors.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
The CRE said office vacancies are a thorny issue, with ripple effects extending beyond commercial real estate. According to HousingWire, DellaPelle cited a recent transaction in which a $32 million assessed office building sold for just $8.5 million, marking the value reset occurring in many markets. Those devaluations threaten local tax bases and could force municipalities to shift tax burdens onto residential property owners. The housing market faces its own set of challenges, <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">particularly around affordability and inventory constraints</a>. Demographics play a role, according to the report, with many older homeowners choosing to stay put rather than trade up at higher interest rates. &#8220;Why would I sell my house and buy a new one, taking on a 7% mortgage to get a smaller house that is going to end up costing me more than my big house?&#8221; DellaPelle said.
See Also: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Sustainability concerns continue to gain prominence, driven by regulatory changes and shifting consumer preferences. Property owners face mounting pressure to understand and reduce their carbon footprints, while younger buyers increasingly prioritize climate resilience in their purchasing decisions.
The geopolitical landscape adds another layer. Global conflicts and political shifts can quickly impact supply chains, construction costs and investment patterns. The report highlights how international tensions often drive foreign capital into U.S. real estate markets as investors seek safe havens.
The report suggests that success in this challenging environment requires careful attention to demographic trends and population movements. &#8220;You have to anticipate where they [people] are going,&#8221; DellaPelle said.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'The Days Of Free Money Are Over': 2025 Real Estate Predictions From CRE's Top Ten Issues Report

Ares Management's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) short percent of float has risen 3.4% since its last report. The company recently reported that it has 3.90 million shares sold short, which is 2.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ares Management Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732544111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ares Management has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ares Management's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ares Management's peer group average for short interest as a percentage of float is 3.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARES

(ARES) - Analyzing Ares Management's Short Interest

WIIM

INTC

Intel shares are trading higher following a report indicating the company is close to finalizing a deal with the CHIPS Act Office for an $8 billion grant.

<ul>
<li>Intel and the Commerce Department are close to finalizing a roughly $8 billion grant for the struggling chipmaker, according to a person familiar with the matter.</li>
<li>The grant will support Intel's chip manufacturing expansion.</li>
<li>In recent quarters, Intel has looked to raise cash by selling off assets and faced a possible takeover bid from Qualcomm.</li>
</ul>
<a href="https://www.cnbc.com/2024/11/25/intel-close-to-8-billion-chips-act-grant-source.html" title="https://www.cnbc.com/2024/11/25/intel-close-to-8-billion-chips-act-grant-source.html">https://www.cnbc.com/2024/11/25/intel-close-to-8-billion-chips-act-grant-source.html</a>

Macro Notification

General

'Intel and Commerce Department close to finalizing roughly $8 billion CHIPS Act grant, source says' - CNBC

Warning: NBTX is at high risk of performing badly

Nanobiotix (NBTX) has released an update. Nanobiotix has made significant strides in its nanoparticle-based therapeutic platforms, highlighted by t...

Nanobiotix Strengthens Growth and Financial Prospects

Clémence Thiers, an analyst from Stifel Nicolaus, maintained the Buy rating on Nanobiotix (0QAV – Research Report). The associated price target rem...

Nanobiotix's Strategic Growth and Financial Stability Underpin Buy Rating

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Nanobiotix (0QAV – Research Report). The associated price tar...

Strategic Partnership and Financial Stability Drive Buy Rating for Nanobiotix Amidst Promising Cancer Study Developments

Nanobiotix (NBTX) has released an update. Nanobiotix, a pioneering biotechnology company based in Paris, is pushing the boundaries of treatment pos...

Nanobiotix's Market Influence and Innovation Unveiled

Analyst Jonathan Chang of Leerink Partners reiterated a Buy rating on Nanobiotix (NBTX – Research Report), retaining the price target of $11.00. Jo...

Optimistic Buy Rating for Nanobiotix: Promising Pipeline Progress and Strategic Partnerships

NBTX

Earnings

Press Releases

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Comments

Nanobiotix

Notizie

Ultime notizie per Nanobiotix (NASDAQ:NBTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO